undamentalytics Newsletter

Papadopoulos Stelios: insider trades

Director at 2 companies we cover. 2 open-market purchases and 12 sales not made under a pre-set plan, reported from August 25, 2010 to November 13, 2025.

Would copying Papadopoulos Stelios’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 28, 2015 into $11,653 by November 2, 2026, +1.4% a year. The copy held shares only 9% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $13,647, +2.8% a year (the S&P 500 held throughout made $43,453, +14.0% a year). Beta against the index was 0.10. Twelve months after each report, the average purchase was −15.6% against the S&P 500 (median −15.6%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −14.3%. After their sales, the shares moved −14.9% against the index over 12 months on average (a negative figure means selling was the right call); 91% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $43.5k$13.6k$11.7k
Copying Papadopoulos SteliosS&P 500, same days investedS&P 500, held throughout $10,000 copying Papadopoulos Stelios’s open-market purchases from July 28, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+1.4%
S&P 500, same days invested
+2.8% (held throughout +14.0%)
Time in shares
9%
Sharpe ratio (S&P 500)
−0.03 (0.70)
Biggest drop (S&P 500)
−33% (−34%)
Market sensitivity (beta)
0.10
Purchases copied
1

Trade by trade

Papadopoulos Stelios: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −13.6% −13.6% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 −5.5% −5.5% 0% 1 — — Not enough years
Purchases, 12 months after the report 1 −15.6% −15.6% 0% 1 — — Not enough years
Purchases, 12 months after the trade 1 −14.3% −14.3% 0% 1 — — Not enough years
Sales, 3 months after the report 12 −7.6% −8.7% 67% 8 −1.51 0.17 No reliable evidence
Sales, 12 months after the report 11 −14.9% −18.9% 91% 8 −0.62 0.56 No reliable evidence
Sales, 12 months after the trade 11 −14.9% −18.3% 91% 8 −0.61 0.56 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Exelixis, Inc. EXEL —112August 25, 2010November 13, 2025
Biogen BIIB —10July 27, 2015July 27, 2015

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
November 13, 2025November 12, 2025 EXEL Sale $4,355,000 +4.3%not yetnot yet
May 16, 2025May 15, 2025 EXEL Sale $1,619,130 −23.9%−14.4%−18.8%
May 22, 2024May 20, 2024 EXEL Sale $240,177 +19.6%+94.6%+92.1%
February 24, 2022February 22, 2022 EXEL Sale $1,653,113 −2.7%−7.4%−5.9%
May 13, 2021May 11, 2021 EXEL Sale $518,794 −35.9%−19.1%−17.5%
May 8, 2020May 8, 2020 EXEL Sale $1,162,800 −36.0%−53.8%−49.2%
February 22, 2019February 21, 2019 EXEL Sale $557,812 −10.6%−27.2%−23.1%
May 7, 2018May 7, 2018 EXEL Sale $332,250 −9.8%−18.8%−18.3%
March 2, 2018March 2, 2018 EXEL Sale $360,750 −20.3%−12.0%−10.7%
September 22, 2017September 22, 2017 EXEL Sale $254,000 +18.2%−45.4%−49.9%
September 20, 2017September 18, 2017 EXEL Sale $5,535,387 −7.6%−59.4%−57.6%
March 21, 2017March 20, 2017 EXEL Sale $216,600 +13.1%−0.9%−5.4%
July 27, 2015July 27, 2015 BIIB Purchase $3,048,800 −13.6%−15.5%−14.3%
August 25, 2010August 24, 2010 EXEL Purchase $610,398 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Papadopoulos Stelios traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.